BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38453105)

  • 1. Exploring therapeutic potential of Rutin by investigating its cyclin-dependent kinase 6 inhibitory activity and binding affinity.
    Yousuf M; Khan S; Hussain A; Alajmi MF; Shamsi A; Haque QMR; Islam A; Hassan MI
    Int J Biol Macromol; 2024 Apr; 264(Pt 2):130624. PubMed ID: 38453105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
    Yousuf M; Shamsi A; Khan P; Shahbaaz M; AlAjmi MF; Hussain A; Hassan GM; Islam A; Rizwanul Haque QM; Hassan MI
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics.
    Yousuf M; Shamsi A; Mohammad T; Azum N; Alfaifi SYM; Asiri AM; Mohamed Elasbali A; Islam A; Hassan MI; Haque QMR
    ACS Omega; 2022 Jul; 7(29):25844-25852. PubMed ID: 35910117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naringenin as a potential inhibitor of human cyclin-dependent kinase 6: Molecular and structural insights into anti-cancer therapeutics.
    Yousuf M; Shamsi A; Khan S; Khan P; Shahwan M; Elasbali AM; Haque QMR; Hassan MI
    Int J Biol Macromol; 2022 Jul; 213():944-954. PubMed ID: 35690164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
    Khuntawee W; Rungrotmongkol T; Hannongbua S
    J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing.
    Baig MH; Yousuf M; Khan MI; Khan I; Ahmad I; Alshahrani MY; Hassan MI; Dong JJ
    Front Oncol; 2022; 12():865454. PubMed ID: 35720007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach.
    Madhana Priya N; Balasundaram A; Sidharth Kumar N; Udhaya Kumar S; Thirumal Kumar D; Magesh R; Zayed H; George Priya Doss C
    Adv Protein Chem Struct Biol; 2023; 135():97-124. PubMed ID: 37061342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches.
    Luo X; Zhao Y; Tang P; Du X; Li F; Wang Q; Li R; He J
    Mol Divers; 2021 Feb; 25(1):367-382. PubMed ID: 32770459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies.
    Yousuf M; Shamsi A; Queen A; Shahbaaz M; Khan P; Hussain A; Alajmi MF; Rizwanul Haque QM; Imtaiyaz Hassan M
    J Cell Biochem; 2021 Aug; 122(8):897-910. PubMed ID: 33829554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced state transition barrier of CDK6 from open to closed state induced by Thr177 phosphorylation and its implication in binding modes of inhibitors.
    He H; Xu J; Xie W; Guo QL; Jiang FL; Liu Y
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):501-512. PubMed ID: 29108955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy.
    Yousuf M; Khan P; Shamsi A; Shahbaaz M; Hasan GM; Haque QMR; Christoffels A; Islam A; Hassan MI
    ACS Omega; 2020 Oct; 5(42):27480-27491. PubMed ID: 33134711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
    Lu H; Chang DJ; Baratte B; Meijer L; Schulze-Gahmen U
    J Med Chem; 2005 Feb; 48(3):737-43. PubMed ID: 15689157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive hybrid paradigm for cytotoxic activity of 1,3,4-thiadiazole derivatives as CDK6 inhibitors against human (MCF-7) breast cancer cell line and its structural modifications: rational for novel cancer therapeutics.
    Chukwuemeka PO; Umar HI; Iwaloye O; Oretade OM; Olowosoke CB; Oretade OJ; Elabiyi MO
    J Biomol Struct Dyn; 2022 Nov; 40(18):8518-8537. PubMed ID: 33890551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the therapeutic potential of rutin through investigating its inhibitory mechanism on lactate dehydrogenase: Multi-spectral methods and computer simulation.
    Ding P; Yang K; Wang H; Kuang L; Gao L; Luo J; Tuo X
    Bioorg Chem; 2024 Aug; 149():107503. PubMed ID: 38823312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unveiling Conformational States of CDK6 Caused by Binding of Vcyclin Protein and Inhibitor by Combining Gaussian Accelerated Molecular Dynamics and Deep Learning.
    Zhao L; Wang J; Yang W; Zhao K; Sun Q; Chen J
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex.
    Zhang J; Zhang L; Xu Y; Jiang S; Shao Y
    PLoS One; 2018; 13(5):e0196651. PubMed ID: 29715320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations.
    Susanti NMP; Damayanti S; Kartasasmita RE; Tjahjono DH
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
    Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
    Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells.
    Van Dross R; Yao S; Asad S; Westlake G; Mays DJ; Barquero L; Duell S; Pietenpol JA; Browning PJ
    J Natl Cancer Inst; 2005 May; 97(9):656-66. PubMed ID: 15870436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CDK6 in cancer: State of the art and new insights.
    Tadesse S; Yu M; Kumarasiri M; Le BT; Wang S
    Cell Cycle; 2015; 14(20):3220-30. PubMed ID: 26315616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.